Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (101-110 of 237) with videos related to

Pageof 24
Sort By:
Cancer Biology & Therapy|March 19, 2003
The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53Masaki Kitazono, Susan Bates, Patrick Fok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Clinical Trials (London, England)|October 25, 2021
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trialsAdélaïde Doussau, Isha Agarwal, Tito Fojo, et al.
The Lancet. Oncology|January 5, 2024
Mitotane and the myth of 14 mg/LMatthew I Ehrlich, Brian W Labadie, Susan E Bates, et al.
The Oncologist|August 28, 2010
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progressionRavi A Madan, James L Gulley, Tito Fojo, et al.
Plos One|May 7, 2014
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as exampleMauricio Burotto, Julia Wilkerson, Wilfred Stein, et al.
Cancer|April 8, 2011
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancyErin E Patterson, Alisha K Holloway, Julie Weng, et al.
The Oncologist|February 19, 2016
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology MeetingPaul R Massey, Ruibin Wang, Vinay Prasad, et al.
Cancer Research|December 17, 2005
Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samplesLyn Mickley Huff, Zheng Wang, Angel Iglesias, et al.
Seminars in Oncology|February 11, 2019
Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomesMauricio Burotto, Julia Wilkerson, Wilfred D Stein, et al.
Pageof 24

Showing results (101-110 of 237) with videos related to

Sort By:
Pageof 24
Cancer Biology & Therapy|March 19, 2003
The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53Masaki Kitazono, Susan Bates, Patrick Fok, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Challenges of evaluating the cardiac effects of anticancer agentsSusan E Bates, Douglas R Rosing, Tito Fojo, et al.
Clinical Trials (London, England)|October 25, 2021
Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trialsAdélaïde Doussau, Isha Agarwal, Tito Fojo, et al.
The Lancet. Oncology|January 5, 2024
Mitotane and the myth of 14 mg/LMatthew I Ehrlich, Brian W Labadie, Susan E Bates, et al.
The Oncologist|August 28, 2010
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progressionRavi A Madan, James L Gulley, Tito Fojo, et al.
Plos One|May 7, 2014
Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as exampleMauricio Burotto, Julia Wilkerson, Wilfred Stein, et al.
Cancer|April 8, 2011
MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancyErin E Patterson, Alisha K Holloway, Julie Weng, et al.
The Oncologist|February 19, 2016
Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology MeetingPaul R Massey, Ruibin Wang, Vinay Prasad, et al.
Cancer Research|December 17, 2005
Aberrant transcription from an unrelated promoter can result in MDR-1 expression following drug selection in vitro and in relapsed lymphoma samplesLyn Mickley Huff, Zheng Wang, Angel Iglesias, et al.
Seminars in Oncology|February 11, 2019
Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomesMauricio Burotto, Julia Wilkerson, Wilfred D Stein, et al.
Pageof 24